Bipolar Disorder Management
For acute mania, initiate treatment with lithium, valproate, or a second-generation antipsychotic (aripiprazole, olanzapine, quetiapine, risperidone, or ziprasidone); for maintenance therapy, use lithium or valproate for at least 2 years; and always combine pharmacotherapy with psychoeducation for patients and families.
Acute Mania Treatment
Pharmacotherapy is the primary treatment for acute manic episodes 1, 2. The choice should be based on:
- Evidence of efficacy
- Phase of illness
- Presence of psychotic symptoms or rapid cycling
- Side effect profile and safety
- Patient's prior medication response
- Family history of treatment response (parental response may predict offspring response) 1
First-Line Options for Acute Mania:
Mood Stabilizers:
- Lithium (FDA-approved down to age 12 for acute mania and maintenance) 1, 2
- Valproate/Divalproex 1, 2
- Carbamazepine 2
Second-Generation Antipsychotics (all FDA-approved for acute mania in adults):
- Aripiprazole
- Olanzapine
- Quetiapine
- Risperidone
- Ziprasidone 1
For resource-limited settings: Haloperidol is recommended, with second-generation antipsychotics as alternatives if cost and availability permit 2.
Mixed Episodes:
Valproate or atypical antipsychotics are preferred over lithium 4.
Bipolar Depression Treatment
Treatment of bipolar depression remains less satisfactory than mania treatment 3.
First-Line Options:
- Quetiapine (strongest monotherapy evidence) 5, 6, 4
- Olanzapine-fluoxetine combination (FDA-approved for bipolar depression) 1, 6, 4
- Lamotrigine (effective for depression but not mania) 1, 6, 7
- Lurasidone 3
Critical Antidepressant Caveat:
Antidepressants must ALWAYS be combined with a mood stabilizer (lithium or valproate) 2, 8. When used:
- Prefer SSRIs (fluoxetine) over tricyclic antidepressants 2
- Risk of inducing mania/hypomania, mixed episodes, or rapid cycling when given as monotherapy 1
- A manic episode precipitated by an antidepressant is classified as substance-induced per DSM-IV-TR 1
- Antidepressant use remains controversial with strongest evidence showing them as triggers for manic relapse 9
Long-Term Maintenance Treatment
Lithium or valproate should be used for maintenance treatment, continuing for at least 2 years after the last episode 2.
Maintenance Options with Evidence:
- Lithium (strongest evidence for long-term relapse prevention and unique antisuicide effects) 5, 3
- Valproate 2
- Lamotrigine (FDA-approved for maintenance in adults) 1
- Olanzapine (FDA-approved for maintenance in adults) 1
- Aripiprazole 10
Decision to continue beyond 2 years should be made by a mental health specialist 2.
Evidence Strength Note:
While lithium has the strongest long-term evidence, anticonvulsants like divalproex and lamotrigine have less robust data, and considerable uncertainty exists about longer-term benefits of antipsychotics 5.
Psychosocial Interventions
Psychoeducation should be routinely offered to all patients with bipolar disorder and their family members/caregivers 2.
Additional Evidence-Based Psychosocial Options:
- Cognitive behavioral therapy 2
- Family-focused interventions 2
- Group psychoeducation (best evidence-based intervention) 6
- Social skills training (in association with other interventions) 2
Long-term maintenance and acute stabilization of depression can be enhanced by combining psychosocial treatments with medications 5.
Treatment Algorithm by Phase
For Acute Mania:
- Start lithium, valproate, OR second-generation antipsychotic
- If psychotic features present: prefer antipsychotic or combination
- If rapid cycling: prefer valproate or antipsychotic over lithium
- Add benzodiazepines short-term for acute agitation/sleep disturbance (caution in young children due to disinhibition risk) 1
For Bipolar Depression:
- Start quetiapine, olanzapine-fluoxetine combination, OR lamotrigine
- If adding antidepressant: MUST combine with lithium or valproate
- Monitor closely for mood destabilization or switch to mania
For Maintenance:
- Continue lithium or valproate for minimum 2 years
- Consider lamotrigine if depression predominates
- Maintain psychoeducation throughout
Critical Safety Considerations
- Avoid unnecessary polypharmacy despite frequent need for multiple agents 1
- Lithium requires close clinical and laboratory monitoring 2
- Valproate has specific MHRA safety measures that must be followed 8
- Monitor for extrapyramidal side effects with antipsychotics; avoid routine anticholinergic prophylaxis 2
- Carbamazepine requires HLA genotyping in certain populations to avoid severe cutaneous reactions 8
- Antidepressants are the trigger with strongest evidence for manic relapse 9
Special Populations
For children and adolescents (age 12+): Lithium is the only FDA-approved agent, though clinical practice commonly uses mood stabilizers and antipsychotics off-label 1. Evidence in youth is sparse and derived primarily from adult literature.
For treatment-refractory cases: Clozapine may be considered only when diagnosis is well-established, given its side-effect profile 1.